Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)

Table 5

Changes in fat distribution on CT scanning.

Parameters	Group	0 month	12 months	P-value	Difference	P-value
Visceral fat area (cm^2)	T	188.8±73.7	188.8±92.3	0.695	0.0±47.5
	L	170.8±51.1	181.5±23.6	0.345	10.7±35.5	0.353
Subcutaneous fat area (cm^2)	T	257.1±150.4	252.7±171.5	0.875	−4.4±52.0
	L	252.9±76.1	253.8±65.5	0.834	0.9±27.2	0.933
Visceral to subcutaneous fat ratio	T	0.92±0.57	1.12±1.02	0.754	0.19±0.74
	L	0.71±0.26	0.75±0.19	0.176	0.05±0.15	0.398
Liver to spleen ratio	T	0.82±0.25	0.97±0.22	0.049	0.16±0.24
	L	1.01±0.23	1.01±0.21	>0.999	0.00±0.16	0.272

Data are presented as mean ± SD. Parameters at 0 and 12 months of treatment were compared by Wilcoxon's matched-pair signed-rank test. Differences are shown as [value at 12 months − value at 0 month]. Differences between groups (telmisartan (T) versus losartan (L)) were compared by Mann-Whitney 𝑈 test.
CT: computer tomography.